RxDoctor Payments Data

Daniel Goodwin, MD

Cardiovascular Disease · Portland, ORNPI 1407972821

Payments from drug & device makers

$2,444in general payments, 2019–2025

Across 8 payments — averaging $305.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • AstraZeneca$125
  • Boehringer Ingelheim$124
  • E.r. Squibb & Sons, L.L.C.$28
  • Novartis$20
  • Boston Scientific$18
  • plus $29 from 2 others

What the payments were for

  • Consulting fees$2,10086%
  • Food & beverage$34414%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,444 in reported general payments places this provider in the 60th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$145,660
Medicare patients
2,123
Services billed
3,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban428$607,566
JardianceEmpagliflozin146$175,288
XareltoRivaroxaban76$98,760
EntrestoSacubitril/Valsartan66$95,941
FarxigaDapagliflozin Propanediol19$24,559
Repatha SureclickEvolocumab12$18,975
Metoprolol Succinate498$8,710
Ranolazine ErRanolazine19$6,367
NexlizetBempedoic Acid/Ezetimibe12$5,693
Atorvastatin Calcium333$5,538
Losartan Potassium278$3,162
Ezetimibe50$2,090
Rosuvastatin Calcium143$1,981
Carvedilol236$1,914
ClopidogrelClopidogrel Bisulfate149$1,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$124$175,288146 claims
NovartisEntresto$20$95,94166 claims
AstraZenecaFarxiga$125$24,55919 claims
Esperion Therapeutics, Inc.Nexlizet$14$5,69312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →